BTIG Maintains Buy on Abivax, Raises Price Target to $175
Benzinga Newsdesk 4 months ago
Analyst RatingsNewsPrice Target
BTIG analyst Julian Harrison maintains Abivax (NASDAQ:ABVX) with a Buy and raises the price target from $150 to $175.
BTIG analyst Julian Harrison maintains Abivax (NASDAQ:ABVX) with a Buy and raises the price target from $150 to $175.